{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:09:03Z","timestamp":1770818943136,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.diabres.2019.107879","type":"journal-article","created":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T09:56:02Z","timestamp":1570960562000},"page":"107879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Metformin lactic acidosis: Should we still be afraid?"],"prefix":"10.1016","volume":"157","author":[{"given":"Teresa","family":"Salvatore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia Clara","family":"Pafundi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Marfella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celestino","family":"Sardu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ricozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Imbriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Nevola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Elio","family":"Adinolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando Carlo","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2019.107879_b0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/diaspect.27.2.82","article-title":"A brief history of the development of diabetes medications","volume":"27","author":"White","year":"2014","journal-title":"Diabetes Spectr"},{"issue":"9","key":"10.1016\/j.diabres.2019.107879_b0010","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2019.107879_b0015","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20132019. Diabetes Care. 2019;42(Suppl 1):S90\u2013S102.","DOI":"10.2337\/dc19-S009"},{"issue":"12","key":"10.1016\/j.diabres.2019.107879_b0020","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Dia Care"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0025","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2019.107879_b0030","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S29\u2013S33.","DOI":"10.2337\/dc19-S003"},{"key":"10.1016\/j.diabres.2019.107879_b0035","first-page":"111","article-title":"Incidence of severe side effects during therapy with sulfonylureas and biguanides","volume":"15","author":"Berger","year":"1985","journal-title":"Horm Metab Res Suppl"},{"issue":"2","key":"10.1016\/j.diabres.2019.107879_b0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0045","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"25","author":"Salpeter","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.diabres.2019.107879_b0050","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2019.107879_b0055","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"14","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"10.1016\/j.diabres.2019.107879_b0060","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.diabres.2019.107879_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196122","article-title":"Risk of lactic acidosis in type 2 diabetes patients using metformin: a case control study","volume":"13","author":"Aharaz","year":"2018","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.diabres.2019.107879_b0070","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet Genom"},{"issue":"7506","key":"10.1016\/j.diabres.2019.107879_b0075","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.diabres.2019.107879_b0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/0885066605278644","article-title":"Lactic acidosis: from sour milk to septic shock","volume":"20","author":"Fall","year":"2005","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.diabres.2019.107879_b0085","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/diab.46.9.1406","article-title":"Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver","volume":"46","author":"Radziuk","year":"1997","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.diabres.2019.107879_b0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.diabres.2019.107879_b0095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2019.107879_b0100","unstructured":"Reference ID: 4079198 \u2013 FDA. GLUMETZA\u00ae (metformin hydrochloride extended-release tablets), Initial U.S. Approval: 1995. Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC. Bridgewater, NJ; 04\/2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021748s020lbl.pdf. Accessed on April 08, 2019."},{"key":"10.1016\/j.diabres.2019.107879_b0105","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2169\/internalmedicine.55.5415","article-title":"A fatal case of metformin-associated lactic acidosis","volume":"55","author":"Ozeki","year":"2016","journal-title":"Intern Med"},{"issue":"11","key":"10.1016\/j.diabres.2019.107879_b0110","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/dom.12974","article-title":"Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm","volume":"19","author":"Lalau","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.diabres.2019.107879_b0115","doi-asserted-by":"crossref","first-page":"908.e3","DOI":"10.1016\/j.ajem.2018.01.097","article-title":"Metformin-Induced Lactic Acidosis (MILA): review of current diagnostic paradigm","volume":"36","author":"Krowl","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.diabres.2019.107879_b0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/FPC.0b013e32834c0010","article-title":"The pharmacogenetics of metformin and its impact on plasma metformin steadystate levels and glycosylated hemoglobin A1c","volume":"21","author":"Christensen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.diabres.2019.107879_b0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2050-6511-14-22","article-title":"The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis","volume":"14","author":"Kajbaf","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1463-1326.2001.00128.x","article-title":"Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'","volume":"3","author":"Lalau","year":"2001","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2019.107879_b0135","article-title":"Review of Biguanide (Metformin) Toxicity","volume":"21","author":"Wang","year":"2018","journal-title":"J Intensive Care Med"},{"issue":"7","key":"10.1016\/j.diabres.2019.107879_b0140","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/CCM.0b013e3181a02490","article-title":"Metformin-associated lactic acidosis: a prognostic and therapeutic study","volume":"37","author":"Seidowsky","year":"2009","journal-title":"Crit Care Med"},{"issue":"20","key":"10.1016\/j.diabres.2019.107879_b0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13054-015-1180-6","article-title":"actic acidosis and severe septic shock in metformin users: a cohort study","volume":"15","author":"Doenyas-Barak","year":"2016","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.diabres.2019.107879_b0150","first-page":"363","article-title":"A review on the protective effects of metformin in sepsis-induced organ failure","volume":"21","author":"Ismail Hassan","year":"2020","journal-title":"Cell J."},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/dme.12017","article-title":"The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database","volume":"30","author":"Kajbaf","year":"2013","journal-title":"Diabet Med"},{"issue":"943","key":"10.1016\/j.diabres.2019.107879_b0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/pgmj.2002.004291","article-title":"Hyperglycaemic crises and lactic acidosis in diabetes mellitus","volume":"80","author":"English","year":"2004","journal-title":"Postgrad Med J"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diabet.2013.02.006","article-title":"Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes","volume":"39","author":"Scheen","year":"2013","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2019.107879_b0170","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2337\/dc13-3023","article-title":"Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study","volume":"37","author":"Eppenga","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2019.107879_b0175","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register","volume":"2","author":"Ekstr\u00f6m","year":"2012","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.diabres.2019.107879_b0180","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2337\/dc14-0464","article-title":"Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study","volume":"37","author":"Richy","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0185","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jamainternmed.2014.6936","article-title":"Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on Food and Drug Administration contraindications","volume":"175","author":"Flory","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.diabres.2019.107879_b0190","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern Med."},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2019.107879_b0200","doi-asserted-by":"crossref","unstructured":"Sharma K, Satriano J. Beneficial effects of AMP-activated protein kinase agonists in kidney ischemia-reperfusion: autophagy and cellular stress markers. Nephron Exp Nephrol. 2014; http:\/\/doi.org\/10.1159\/000368932. [Epub ahead of print].","DOI":"10.1159\/000368932"},{"issue":"4","key":"10.1016\/j.diabres.2019.107879_b0205","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3109\/0886022X.2016.1149770","article-title":"Metformin alleviated EMT and fibrosis after renal ischemia-reperfusion injury in rats","volume":"38","author":"Wang","year":"2016","journal-title":"Renal Fail"},{"key":"10.1016\/j.diabres.2019.107879_b0210","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1038\/srep23975","article-title":"Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPKalpha-regulated autophagy induction","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010042","article-title":"Metformin: a candidate drug for renal diseases","volume":"20","author":"Corremans","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.diabres.2019.107879_b0220","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1159\/000370034","article-title":"Metformin use in kidney transplant recipients in the United States: an observational study","volume":"40","author":"Stephen","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.diabres.2019.107879_b0225","article-title":"Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care","volume":"352","author":"Hippisley-Cox","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12882-017-0579-5","article-title":"Risk of acute kidney injury and survival in patients treated with metformin: an observational cohort study","volume":"18","author":"Bell","year":"2017","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0235","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","article-title":"Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review","volume":"166","author":"Crowley","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0240","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.kint.2018.01.027","article-title":"Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder","volume":"94","author":"Neven","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010042","article-title":"Metformin: a candidate drug for renal disease","volume":"20","author":"Corremans","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2019.107879_b0250","first-page":"4696182","article-title":"A unique case of metformin-associated lactic acidosis","volume":"2018","author":"Gershkovich","year":"2018","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.diabres.2019.107879_b0255","doi-asserted-by":"crossref","first-page":"4350712","DOI":"10.1155\/2016\/4350712","article-title":"The impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms on metformin therapeutic efficacy in Chinese type 2 diabetes patients","volume":"2016","author":"Xiao","year":"2016","journal-title":"Int J Endocrinol"},{"issue":"2","key":"10.1016\/j.diabres.2019.107879_b0260","first-page":"227","article-title":"Is it necessary to discontinue metformin in diabetic patients with GFR > 60 ml\/min per 1.73 m2 undergoing coronary angiography: a controversy still exists?","volume":"89","author":"Namazi","year":"2018","journal-title":"Acta Biomed"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0265","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ihj.2017.05.009","article-title":"Metformin in heart failure patients","volume":"70","author":"Kinsara","year":"2018","journal-title":"Indian Heart J"},{"issue":"5","key":"10.1016\/j.diabres.2019.107879_b0270","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","article-title":"Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study","volume":"111","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.diabres.2019.107879_b0275","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2337\/dc09-2227","article-title":"Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case\u2013control study from the U.K. General Practice Research Database","volume":"33","author":"MacDonald","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0280","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.diabres.2019.107879_b0285","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cardfail.2009.10.022","article-title":"Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes","volume":"16","author":"Shah","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabres.2019.107879_b0290","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13652","article-title":"Heart Failure in the diabetic patient: epidemiology, etiology, prognosis, therapy and the effect of glucose lowering medications","author":"Bell","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"19","key":"10.1016\/j.diabres.2019.107879_b0295","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1161\/CIRCULATIONAHA.108.798561","article-title":"Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase","volume":"119","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0300","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/CIRCRESAHA.108.190918","article-title":"Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure","volume":"104","author":"Gundewar","year":"2009","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0305","doi-asserted-by":"crossref","first-page":"H239","DOI":"10.1152\/ajpheart.01269.2005","article-title":"AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B","volume":"291","author":"Bertrand","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"10.1016\/j.diabres.2019.107879_b0310","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2337\/db10-0351","article-title":"Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice","volume":"60","author":"Xie","year":"2011","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0315","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40256-018-0266-3","article-title":"Cardioprotection by metformin: beneficial effects beyond glucose reduction","volume":"18","author":"Varjabedian","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.diabres.2019.107879_b0320","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.diabres.2019.107879_b0325","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1464-5491.2010.03093.x","article-title":"High prevalence of diabetes mellitus in patients with liver cirrhosis","volume":"27","author":"Wlazlo","year":"2010","journal-title":"Diabet Med"},{"issue":"29","key":"10.1016\/j.diabres.2019.107879_b0330","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.2174\/13816128113199990336","article-title":"Epidemiology and natural history of patients with NAFLD","volume":"19","author":"Bhala","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.diabres.2019.107879_b0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043056","article-title":"Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis","volume":"7","author":"Kita","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.diabres.2019.107879_b0340","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5604\/01.3001.0010.0284","article-title":"Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis","volume":"16","author":"Said","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.diabres.2019.107879_b0345","article-title":"Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?","author":"Green","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0350","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0355","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"issue":"1","key":"10.1016\/j.diabres.2019.107879_b0360","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.23623","article-title":"A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.diabres.2019.107879_b0365","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improved survival of patients with diabetes","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.diabres.2019.107879_b0370","doi-asserted-by":"crossref","first-page":"E987","DOI":"10.1152\/ajpendo.00133.2013","article-title":"Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl\/6 mice","volume":"305","author":"Tajima","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.diabres.2019.107879_b0375","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006888","article-title":"Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients","volume":"96","author":"Ma","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"9131","key":"10.1016\/j.diabres.2019.107879_b0380","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.diabres.2019.107879_b0385","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Steg PG; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2019.107879_b0390","doi-asserted-by":"crossref","first-page":"302.e1","DOI":"10.1016\/j.amjmed.2011.07.033","article-title":"Patterns of metion initiation in newly diagnosed diabetes mellitus: quality and cost implications","volume":"125","author":"Desai","year":"2012","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.diabres.2019.107879_b0395","first-page":"e103","article-title":"Prescriber compliance with black box warnings in older adult patients","volume":"15","author":"Ricci","year":"2009","journal-title":"Am J Manag Care"},{"issue":"5","key":"10.1016\/j.diabres.2019.107879_b0400","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1503\/cmaj.045292","article-title":"Metformin's contraindications should be contraindicated","volume":"173","author":"McCormack","year":"2005","journal-title":"CMAJ"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822719312914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822719312914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:09:47Z","timestamp":1759172987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822719312914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":80,"alternative-id":["S0168822719312914"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2019.107879","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin lactic acidosis: Should we still be afraid?","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2019.107879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107879"}}